- Cristiano E, Rojas JI, Abad P, Adoni T, Barahona J, Becker J, Carrá A, Flores J, Fruns M, Fernández Liguori N, Garcea O, García Bónito J, Giunta D, Gracia F, Hamuy F, Macias Islas MA, Navas C, Boschetti LO, Patrucco L, Sato DK, Correale J. Consensus recommendations for the diagnosis and treatment of primary progressive multiple sclerosis in Latin America. J Neurol Sci. 2018 Oct 15;393:4-13. doi: 10.1016/j.jns.2018.07.024. Epub 2018 Jul 31. PubMed PMID: 30096568.
- Hernández-Ledesma AL, Rodríguez-Méndez AJ, Gallardo-Vidal LS, Trejo-Cruz G,García-Solís P, Dávila-Esquivel FJ. Coping strategies and quality of life in Mexican multiple sclerosis patients: Physical, psychological and social factors relationship. Mult Scler Relat Disord. 2018 Oct;25:122-127.
- Ochoa-Morales A, Hernández-Mojica T, Paz-Rodríguez F, Jara-Prado A,Trujillo-De Los Santos Z, Sánchez-Guzmán MA, Guerrero-Camacho JL, Corona-Vázquez T, Flores J, Camacho-Molina A, Rivas-Alonso V, Dávila-Ortiz de Montellano DJ. Quality of life in patients with multiple sclerosis and its association with depressive symptoms and physical disability. Mult Scler Relat Disord. 2019 Sep9;36:101386. doi: 10.1016/j.msard.2019.101386. [Epub ahead of print] PubMed PMID: 31520986.
- Rivera VM. Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk? Neurol Ther. 2019 Jul 16. doi: 10.1007/s40120-019-0145-0. [Epub ahead of print] PubMed PMID: 31313222.
- Lazo-Gomez R, Velázquez GLL, Mireles-Jacobo D, Sotomayor-Sobrino MA. Mechanisms of neurobehavioral abnormalities in multiple sclerosis: Contributions from neural and immune components. Clin Neurophysiol Pract. 2019 Feb 21;4:39-46. doi: 10.1016/j.cnp.2019.01.004. eCollection 2019. Review. PubMed PMID: 30911699; PubMed Central PMCID: PMC6416523.
- Cristiano E, Rojas JI. Multiple sclerosis epidemiology in Latin America: An updated survey. Mult Scler J Exp Transl Clin. 2017 Jun 13;3(2):2055217317715050. doi: 10.1177/2055217317715050. eCollection 2017 Apr-Jun. PubMed PMID: 28638628; PubMed Central PMCID: PMC5472231.
- Moss BP, Cohen JA. The emergence of follow-on disease-modifying therapies for multiple sclerosis. Mult Scler. 2019 Oct;25(12):1560-1565. doi: 10.1177/1352458519845106. Epub 2019 May 10.
- Mansouri S, Zayeri F. Global and Regional Trends of Multiple SclerosisDisability-Adjusted Life Years Rates: A 25-Year Assessment. Neuroepidemiology. 2019;52(1-2):17-24. doi: 10.1159/000492819. Epub 2018 Nov 26. PubMed PMID: 30476919.
- Negrotto L, Correale J. Evolution of multiple sclerosis prevalence and phenotype in Latin America. Mult Scler Relat Disord. 2018 May;22:97-102. doi: 10.1016/j.msard.2018.03.014. Epub 2018 Mar 21. Review. PubMed PMID: 29649790.
- Steinberg J, Fragoso YD, Duran Quiroz JC, García JR, Guerra C, Rodriguez V, Carcamo Rodriguez C, Ciampi E, Correa-Diaz E, Macías M, Novarro N, Vizcarra D, Oehninger Gatti C, Orozco G, Carrá A. Practical Issues Concerning the Approval and Use of Biosimilar Drugs for the Treatment of Multiple Sclerosis in Latin America. Neurol Ther. 2019 May 24. doi: 10.1007/s40120-019-0139-y. [Epub ahead of print] PubMed PMID: 31127566.